Towards a nanospecific approach for risk assessment  by Dekkers, Susan et al.
lable at ScienceDirect
Regulatory Toxicology and Pharmacology 80 (2016) 46e59Contents lists avaiRegulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate/yrtphTowards a nanospeciﬁc approach for risk assessment
Susan Dekkers a, *, Agnes G. Oomen a, Eric A.J. Bleeker a, Rob J. Vandebriel a,
Christian Micheletti b, Joan Cabellos c, Gemma Janer c, Natalia Fuentes c,
Socorro Vazquez-Campos c, Teresa Borges d, Maria Jo~ao Silva e, Adriele Prina-Mello f,
Dania Movia f, Fabrice Nesslany g, Ana R. Ribeiro h, Paulo Emílio Leite h,
Monique Groenewold a, Flemming R. Cassee a, Adrienne J.A.M. Sips a, Aart Dijkzeul i,
Tom van Teunenbroek i, Susan W.P. Wijnhoven a
a National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
b ECAMRICERT, Vicenza, Italy
c LEITAT, Technological Center, Barcelona, Spain
d Directorate-General of Health (DGS) and PToNANO, Lisbon, Portugal
e National Institute of Health Doutor Ricardo Jorge (INSA) and PToNANO, Lisbon, Portugal
f Trinity College Dublin (TCD), Dublin, Ireland
g Institute Pasteur de Lille (IPL), Lille Cedex, France
h National Institute of Metrology Quality and Technology (INMETRO), Rio de Janeiro, Brazil
i Ministry of Infrastructure and the Environment (Min I&M), The Hague, the Netherlandsa r t i c l e i n f o
Article history:
Received 22 May 2016
Accepted 27 May 2016
Available online 30 May 2016
Keywords:
Nanomaterials
Risk assessment approach
Prioritisation
Grouping
Read-across
(Q)SARs
Testing strategy* Corresponding author.
E-mail address: susan.dekkers@rivm.nl (S. Dekker
http://dx.doi.org/10.1016/j.yrtph.2016.05.037
0273-2300/© 2016 The Authors. Published by Elseviera b s t r a c t
In the current paper, a new strategy for risk assessment of nanomaterials is described, which builds upon
previous project outcomes and is developed within the FP7 NANoREG project. NANoREG has the aim to
develop, for the long term, new testing strategies adapted to a high number of nanomaterials where
many factors can affect their environmental and health impact. In the proposed risk assessment strategy,
approaches for (Quantitative) Structure Activity Relationships ((Q)SARs), grouping and read-across are
integrated and expanded to guide the user how to prioritise those nanomaterial applications that may
lead to high risks for human health. Furthermore, those aspects of exposure, kinetics and hazard
assessment that are most likely to be inﬂuenced by the nanospeciﬁc properties of the material under
assessment are identiﬁed. These aspects are summarised in six elements, which play a key role in the
strategy: exposure potential, dissolution, nanomaterial transformation, accumulation, genotoxicity and
immunotoxicity.
With the current approach it is possible to identify those situations where the use of nanospeciﬁc
grouping, read-across and (Q)SAR tools is likely to become feasible in the future, and to point towards the
generation of the type of data that is needed for scientiﬁc justiﬁcation, which may lead to regulatory
acceptance of nanospeciﬁc applications of these tools.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
It is generally accepted that the recent and upcoming large
variety in nanomaterials provides a challenge for assessing their
risk. Because nanomaterials of the same chemical composition
can have many different physicochemical properties (e.g. size,s).
Inc. This is an open access article ushape, charge, etc.), the variation of different nanoforms is much
larger compared to non-nanomaterials (Maynard et al., 2006).
Whereas it has been indicated that e for now e the risks of
nanomaterials should be assessed on a case-by-case basis for
each individual nanoform with its speciﬁc size, shape, surface
chemistry, etc. (e.g. SCENIHR, 2009; EFSA Scientiﬁc Committee,
2011), it is also recognized that it will require a lot of experi-
mental animals as well as time, effort, and money to obtain for
each case the necessary physicochemical, exposure and hazard
data for all relevant exposure scenarios and endpoints. For ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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explore ways that enable a risk assessment of nanomaterials
without the need to subject each individual nanoform to a full
battery of experimental tests. Important aspects of these new
approaches include amending tools like (Q)SARs, grouping, read-
across and high-throughput screening/testing for nanomaterials.
For successful applicability of such new approaches it is crucial
that sufﬁcient good quality nanospeciﬁc information becomes
available (OECD, 2014a,b; Tantra et al., 2015).
In this paper, we describe a new strategy for risk assessment of
nanomaterials in which we integrate and expand aforementioned
approaches to guide the user how to prioritise those nanomaterial
applications that may lead to high exposure or high toxic potential
and ultimately high risks for human health. Additionally, we
identify those aspects of the exposure, kinetics or hazard assess-
ment that are most likely to be inﬂuenced by the speciﬁc properties
of the nanomaterial(s) under assessment. It is to be noted that the
focus is on human health; the potential risks for environment are
also of importance, though beyond the scope of this paper and
therefore remain to be further investigated in a future dedicated
document. Further, the scientiﬁc knowledge on nanomaterials is
not sufﬁcient yet for deﬁning benchmarks, cut-off values, validation
and subsequent regulatory acceptance of nanospeciﬁc applications
of (Q)SARs, grouping and read-across tools. In this paper the cur-
rent knowledge will be integrated to identify those situations
where the use of such nanospeciﬁc tools is likely to become feasible
and regulatory acceptable in the near future, and to point towards
the generation of the type of data that is needed for regulatory
acceptance.
Currently, there is no indication that nanomaterials will lead to
other toxicological endpoints than those known for non-
nanomaterials (Nel et al., 2014; Donaldson and Poland, 2013;
Gebel et al., 2014). For this reason, current regulatory frame-
works on the safe use of chemicals, such as the regulatory
framework for chemicals REACH (Registration, Evaluation,
Authorisation and restriction of Chemicals; EU2006), are gener-
ally considered suitable to address the risks of nanomaterials (EC,
2012a,b; OECD, 2013). Within Europe REACH Guidance is being
modiﬁed or developed to explain this (ECHA, 2012), while there is
also a call to adapt the legal text, especially with regard to the
information requirements on physicochemical properties (DG
Growth, 2016; Roberts, 2016). Some (European) legislation has
recently been adapted to set rules for the identiﬁcation of nano-
enabled applications (e.g. Cosmetics Regulation EC No 1223/
2009 (EU, 2009) and Biocidal Product Regulation 528/2012 (EU,
2012)). The approach proposed in this paper is developed within
the NANoREG project, which mainly focusses on REACH. However,
in a later stage, it can be made applicable within other regulatory
frameworks as well.
In parallel to the regulatory discussion, there is a scientiﬁc
challenge to provide further insights in the speciﬁc properties that
are crucial in the behaviour and toxicity of nanomaterials. These
insights can aid in performing a proper and efﬁcient risk assess-
ment for nanomaterials in the future, preferably in a way that ac-
celerates the rate at which the information needed for risk
assessment can be generated. The proposed approach described
below, facilitates further development of such insights by
identifying:
a) those applications of nanomaterials that have the highest
potential to cause adverse human health effects (due to high
exposure and/or toxicity)
b) those aspects of exposure, kinetics or hazard that are most
important to address in the human health risk assessment of
nanomaterials,c) those situations where the use of nanospeciﬁc grouping,
read-across and (Q)SARS is likely to become feasible and
potentially regulatory acceptable in the near future, and
d) the type of information needed for this regulatory
acceptance.
The proposed approach is developed to be applicable to nano-
materials that are already on the market. However, elements of this
approach, such as use of grouping and read-across methods and
aspects most important to address the nanospeciﬁc issues within
the risk assessment, will also be applicable to safe innovation ap-
proaches during the development of new nanomaterials in the
research and development phase (Sips et al., 2015).
Nanomaterials are prone to many possible changes during their
life cycle, like (partial) dissolution or degradation, complexation,
aggregation, agglomeration, etc. Because these changes may differ
from the changes of non-nanomaterials, the inﬂuence of these
changes on the exposure and hazard of the nanomaterial should be
assessed throughout its whole life cycle, from the manufacturing of
the nanomaterial, through the different stages of the life cycle,
including various uses, disposal and waste treatment.
The proposed approach is built on the extensive knowledge
already developed in other European research projects or by other
international organisations and committees. The most important
sources of knowledge used are given in Table 1. The existing
knowledge is subdivided in knowledge on newly developed risk
assessment strategies (column 2), read-across and grouping ap-
proaches (column 3) and other supporting information (column 4).
The most recent and relevant publications used in this paper, are
mentioned.
1.1. Current knowledge on the nanospeciﬁc behaviour and toxicity
There is still a lot of debate on the terms nanospeciﬁc behaviour
and toxicity, because differences in the behaviour and toxicity be-
tween nanomaterials and non-nanomaterials are not related to a
nanospeciﬁc threshold below 100 nm, but more likely to be a
gradual magniﬁcation of the intrinsic hazard by decreasing size
(Donaldson and Poland, 2013). Nevertheless, in this paper the
terms nanospeciﬁc behaviour and toxicity are still used to indicate
changes in the response, interaction, behaviour and toxicity asso-
ciated with the decreasing geometrical size of the (nano)materials.
The most distinctive feature of our approach is its focus on
nanospeciﬁc issues in not only the hazard, but also the exposure
assessment and kinetic behaviour. In other words, it makes use of
the speciﬁc physicochemical properties that determine the nano-
speciﬁc behaviour that inﬂuences to what extent and in which way
nanomaterials come into contact and interact with the human
body. Examples of such properties are dissolution rate and reac-
tivity. These properties may change during the life cycle of a
nanomaterial and are partly depending on interactions with the
surrounding environment, which may lead to a different behaviour
of nanomaterials in different situations.
The nanospeciﬁc behaviour is especially relevant for: a) expo-
sure (deposition and agglomeration), b) absorption and distribu-
tion (transport across biological barriers like gut epithelium, blood-
brain barrier, or skin), c) accumulation, and d) toxic potency (dose-
response relationships).
Based on epidemiological and experimental research on the
effects of (ultra)ﬁne particles, it is known that small particles can
cause inﬂammation, ﬁbrosis, lung cancer, cardiovascular effects,
neurodegenerative effects and teratogenic effects (Chen et al., 2016;
Oberdorster et al., 2009). These health effects can also be caused by
non-nanomaterials and are therefore not only restrictive or speciﬁc
for nanomaterials. However, the nanospeciﬁc behaviour can lead to
Table 1
Summary of most important sources of information for the proposed approach.
Sources Types of information used for the current approach
Risk assessment strategy Read-across and grouping
approaches
Other supporting information
MARINA Bos et al., 2015; Oomen et al, 2014 Oomen et al., 2015
GUIDEnano S.W.P. Wijnhoven and P. Van Kesteren, personal
communication
M. Park and G. Janer, personal
communication
ITSnano Stone et al., 2014 Stone et al., 2014 Stone et al., 2014 Intelligent testing strategy for nanomaterials
SUN Malsch et al., 2015
ECETOC Arts et al., 2014, 2015, 2016 Arts et al., 2015 Testing strategy
ECHA/RIVM/
JRC
ECHA, 2013
ECHA, 2016
Regulation (EC) No 1907/2006 (EU, 2006); Hankin et al., 2011 (RIP-oN2
on information requirements);
Aitken et al., 2011 (RIP-oN3 on chemical safety assessment);
ECHA, 2011 (updated chapters of the guidance on IR & CSA)
OECD OECD, 2013 OECD, 2014a,b OECD, 2007e2016 Testing programme of manufactured nanomaterials
SCENIHR SCENIHR, 2009 SCENIHR, 2007 Test guidelines
RIVM/
ARCADIS
Sellers et al., 2015
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fects, e.g. due to the crossing of particular barriers leading to a
(higher) dose at a target site (Donaldson and Poland, 2013). Here, it
should also be realised that where mass is generally used as a dose
descriptor for non-nanomaterials (e.g. mg/m3), other metrics may
be more suitable to compare the toxicity of non-nanomaterials
with nanomaterials (e.g., the surface area of nanomaterials per
m3) (Delmaar et al., 2015). For instance, when effects are caused by
interactions with the surface of a toxicant, nanomaterials may
appear much more toxic than non-nanomaterials using mass as a
dose descriptor due to their relatively high surface area per unit
mass. The dose-response relationship may be similar when surface
area is used as a dose descriptor.
2. Proposed approach
2.1. Elements
Although the strategies summarised in Table 1 have different
aims and anticipated users, there is a considerable overlap in the
various aspects used in the different approaches. This overlap in-
cludes aspects related to the toxicokinetics (such as solubility, ab-
sorption and kinetics), toxicodynamics (such as genotoxicity, and
immunotoxicity), exposure (such as the most relevant routes of
exposure) and aspects that need to be considered when using
grouping or read-across approaches. Using the strategies of Table 1
and the current knowledge on the nanospeciﬁc behaviour
described in the previous paragraphs, six overlapping elements
have been identiﬁed by a small group of NANoREG experts as most
important nanospeciﬁc determinants within the risk assessment of
nanomaterials. The selected elements were subsequently reviewed,
amended and prioritised by a larger group of partners within the
NANoREG project. Below, the six elements are shortly explained
and a short argumentation for the selection of the element is given.
More details on how these elements are incorporated within the
proposed approach can be found in the description of the different
phases.
2.1.1. Exposure potential
Exposure potential is included early in the present approach
because exposure assessment is, in addition to hazard assessment,
essential for performing risk assessment. Although some of the
determinants for exposure (e.g. transformation) are also addressed
in the other elements, these other elements mainly focus on thetoxicokinetics and toxicodynamics of the nanomaterials in relation
to human health effects. The element exposure potential also in-
cludes the other determinants (e.g. routes of exposure or the
amount of nanomaterials used) that are important in identifying
the “hotspots” for exposure throughout the entire lifecycle of the
nanomaterial under assessment.
2.1.2. Dissolution
Dissolution is the key element to identify whether a nano-
material is stable enough to exert nanospeciﬁc behaviour. It is very
important to know if a nanomaterial dissolves into its molecular or
ionic form and how fast, where and under which circumstances
this takes place. If a nanomaterial immediately falls apart into its
molecular or ionic form before it reaches its potential target, it
exerts no nanospeciﬁc behaviour and it is suggested to perform the
classical (non-nanomaterial) risk assessment approach. If not, the
nanospeciﬁc behaviour and effects should be further evaluated.
How dissolution occurs can have a huge impact on the exposure
potential, behaviour and effects of a nanomaterial in humans
(including absorption, translocation to secondary organs and
accumulation in tissues).
2.1.3. Transformation
This element is important since nanomaterials may be trans-
formed during their life cycle. The stability of their original
appearance during manufacturing and the subsequent trans-
formations (including the coating, corona, agglomeration, aggre-
gation and disintegration to smaller units, dissolution,
precipitation, adsorption and desorption, combustion, abrasion,
oxidation and reduction) is very important for their behaviour and
effects in humans and the environment.
2.1.4. Accumulation
The ability of nanomaterials to accumulate in the human body
may increase the likelihood for effects after long-term exposure.
Some nanomaterials have been shown to accumulate in the body.
Although it is not always known if this accumulation results in toxic
effects or not, accumulation is a serious reason for concern in risk
assessment and therefore needs to be included as one of the ele-
ments in our approach.
2.1.5. Genotoxicity
This element is an important mechanism of toxicity, also for
nanomaterials, since genotoxicity is one of the potential
1 Irrespective of the most important information needs identiﬁed within the
proposed approach, information requirements set by regulatory frameworks, e.g.
REACH regulation, should be met.
S. Dekkers et al. / Regulatory Toxicology and Pharmacology 80 (2016) 46e59 49mechanisms that may lead to cancer and, if germ cells are affected,
also to developmental and reproductive effects. It is known that
nanomaterials can induce genotoxicity by directly or indirectly
damaging or interacting with a DNA molecule (Chen et al., 2005;
Donaldson et al., 2010a,b; Singh et al., 2009; Louro et al., 2015).
2.1.6. Immunotoxicity
Another important mechanism of toxicity of nanomaterials is
the onset or triggering of an immune response, causing for example
inﬂammation, immune stimulation or immunosuppression. In its
chronic form, inﬂammation may lead to several health effects such
as ﬁbrosis, cirrhosis, lung cancer, cardiovascular diseases, neuro-
logical diseases, etc. There are different pathways by which nano-
materials can trigger an immune response, but not all cellular
immune responses will lead to notable inﬂammation.
2.2. Main objectives and users of the different phases
The proposed approach consists of different phases, in which
critical aspects of the six elements are addressed. The main ob-
jectives of the approach are:
a) to prioritise those applications of nanomaterials that have the
highest potential to cause human health effects and
b) to identify the most important information needed to address
the nanospeciﬁc issues within the risk assessment.
The ﬁrst objective (prioritisation of applications) is addressed in
the ﬁrst phase, while the second objective (identiﬁcation of infor-
mation) is mainly addressed in the second and further phases.
The objective of the ﬁrst phase is screening and prioritisation.
From this phase, one should be able to get a rough idea on the
potential of a speciﬁc nanomaterial to cause adverse health effects,
by identifying:
a) materials that have the highest potential to be hazardous
(ﬂagged red),
b) materials for which the classical (non-nanomaterial) risk
assessment approach can be performed (ﬂagged green) and
c) materials that need further evaluation (ﬂagged orange).
It is expected that only a few of the nanomaterials that are
currently on the market will fall into the ‘red’ or ‘green’ category,
because manufacturers will probably try to avoid the use of
nanomaterials which may be hazardous or quickly lose their
functionality by falling apart into their ionic or molecular form.
Therefore, the orange group will probably be the largest group, for
which further ranking is needed to indicate a relatively ‘high’,
‘medium’ or ‘ low’ potential to cause harmful effects. Furthermore,
the information obtained in this phase should give direction to
further steps within the information gathering process for risk
assessment by identifying the most relevant exposure scenarios
and possibilities to use read-across and grouping primarily based
on the hazard classiﬁcation of non-nanomaterials or similar
nanomaterials.
The objective of the second and further phases is to identify the
most important information needed to address the nanospeciﬁc
issues within the risk assessment. These phases should give di-
rection to the most important information needed depending on
the speciﬁc application, life cycle stage and exposure situation.
Furthermore, these phases will identify possibilities for grouping
and read-across primarily based on physicochemical properties and
in vitro data.
The proposed approach should be suitable for different uses by
policy makers, regulators and industry. Policy makers andregulators can predominantly beneﬁt from using the ﬁrst phase of
the approach to prioritise those applications that need to be
addressed most urgently. Industry can use the ﬁrst phase to get an
initial impression on the suitability of the application of the
nanomaterial in a speciﬁc product based on the potential of a
speciﬁc nanomaterial to cause adverse health effects during the
different life stages of that product. The second and further phases
can be used by regulators and industry to identify the most
important information needs to address the nanospeciﬁc issues
and/or investigate the possibilities for grouping or read-across.1
In Fig. 1, an overview is given of the different phases with the
various relevant elements depicted for each phase. Each of the six
elements has its own colour. Next to the elements, the different
aspects are depicted in the same colour(s) as the elements they
relate to. More details on the various phases of the ﬂow chart and
elements within that phase are described below.
3. More detailed description of phase I
3.1. Input phase I
In the following section, the reader will be guided through the
ﬁrst phase of the proposed approach (see Fig. 1). Going through the
ﬂow chart, suitable information should be gathered or generated
within each of the boxes. The ﬂow chart starts in phase I on the
upper left side of the ﬁgure, where the dashed black arrow ‘Start’
points to the grey box ‘Nano?’ To determine whether the investi-
gated material is a nanomaterial, information is needed on physi-
cochemical characteristics size and/or surface area. Other
information needed in other boxes of the ﬁrst phase is the aspect
ratio (shape and size), rigidity, biopersistence, dissolution and
reactivity of the nanomaterial. For exposure, possible applications,
production volumes and production process as well as operational
conditions are important. A more detailed description can be found
in the paragraphs underneath. The information needed in the ﬁrst
phase is often available from manufacturers or can be obtained
through analytical or acellular assays. An overview of the relevant
information for going through the entire ﬂow chart is given in
Table SI-1 of the Supplementary information. The way to precede
further in phase I of the ﬂow chart is described for each of the boxes
below.
3.2. Physicochemical characteristics (phase I)
3.2.1. Nano?
The ﬁrst phase starts with determining if the material indeed is
a nanomaterial (see in Fig.1, the dotted line from the left). There has
been a lot of discussion on the deﬁnition of a nanomaterial and
multiple deﬁnitions are used in various international organisations,
committees and jurisdictions all over the world. Here we use the EC
recommendation (European Parliament and Council, 2011) on the
deﬁnition:
‘Nanomaterial’ means a natural, incidental or manufactured
material containing particles, in an unbound state or as an aggre-
gate or as an agglomerate and where, for 50% or more of the par-
ticles in the number size distribution, one or more external
dimensions is in the size range 1 nme100 nm.
This deﬁnition is not a risk based deﬁnition, but is considered
the most appropriate one to be used for regulatory purposes. The
use of this deﬁnitionmight be updated depending on new scientiﬁc
Fig. 1. Overview of the different phases of the ﬂow chart Green arrows: the material is no nanomaterial or has such a high dissolution rate in water that it falls apart into its
molecular or ionic form before it reaches its target ¼> the classical (non-nanomaterial) risk assessment approach can be performed. Red arrow: the material is a “rigid and
biopersistent High Aspect Ratio Nanomaterial (HARN)” ¼> substitution or information gathering for targeted risk assessment to evaluated the potential to cause mesothelioma is
needed. Orange arrows: the material does not meet the criteria for classical (non-nanomaterial) risk assessment or targeted risk assessment to evaluate the potential to cause
mesothelioma ¼> use information of phase I for prioritisation and/or further evaluation following the proposed elements related to the kinetics, toxicity and exposure in phase II, III
and further. Black arrows: evaluation of the nanomaterial following the proposed elements related to the kinetics, toxicity and exposure in phase I, II, III and further.
PROC ¼ process and operational conditions. I: inhalation route of exposure. O: oral route of exposure. D: dermal route of exposure.
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deﬁnition. The analytical methods to determinewhether a material
meets the criteria of the EC recommendation have been evaluated
in different reports by Joint Research Centre (JRC) and within work
package 2 of the NANoREG project (JRC, 2012, 2014a, 2014b; 2015;
De Temmerman et al., 2014). If the material does not meet the
criteria of a nanomaterial as described in the EC recommendation,
it can be evaluated using the information on the chemical com-
position(s) of the non-nanomaterial (follow the green arrow in
Fig. 1), effectively leaving the current approach. If the material does
meet the criteria of a nanomaterial, the black arrow in Fig. 1 shouldbe followed and dissolution in water should be evaluated.
3.2.2. Dissolution rate and equilibrium in water
The water solubility is conventionally measured using the OECD
Test Guideline (TG) 105, which deﬁnes the water solubility of a
substance as the saturation mass concentration of the substance in
water at a given temperature and proposes two methods to mea-
sure it for conventional substances (the column elution method
and the ﬂask method). This OECD TG is already used for aggregated
and agglomerated nanomaterials but it needs to be revised and
reﬁned especially for nanomaterials that disperse into small
Table 2
Ranking of the occupational exposure potential in phase I based on production
volume and PROCs of the most important occupational scenarios within the life
cycle of each application of the nanomaterial.
PROCa Production volume
high medium low
high high high high
medium high medium medium
low medium low low
a Process and Operational Conditions (PROCs) for occupational exposure.
S. Dekkers et al. / Regulatory Toxicology and Pharmacology 80 (2016) 46e59 51primary nanoparticles (OECD, 2014a,b). Several approaches for the
risk assessment of nanomaterials propose to use the outcomes of
these types of tests to distinguish soluble from non-soluble nano-
materials (BAuA, 2013; Arts et al., 2015, 2016). However, as no
equilibrium will be reached in many situations relevant for human
health risk assessment, the water solubility does not provide suf-
ﬁcient insight in the possibility of uptake of nanomaterials as
physiologically relevant time frames are not considered (Oomen
et al., 2015). It might be more informative to use the dissolution
rate, because the informationwhether a nanomaterial will fall apart
into its molecular or ionic form and at what rate before (or after) it
reaches its potential target is far more relevant. OECD GD 29 de-
scribes how the dissolution rate of metals and metal compounds in
aqueous media can be measured. However, there are no nano-
speciﬁc guidelines for such tests and also no proposed cut-off
values to distinguish soluble from non-soluble nanomaterials are
proposed (Tantra et al., 2015). Therefore, a comparison of the
dissolution rate of the nanomaterial to that of the chemical com-
ponents of which it is composed, might give an indication on the
possibility to use the data of the non-nanomaterial (read-across). If
a nanomaterial has a very fast dissolution rate (i.e. close to instantly
dissolved), the nanomaterial can be evaluated using the informa-
tion on the chemical composition(s) of the non-nanomaterial
(follow the green arrow in Fig. 1 towards the box “classical (non-
nanomaterial) approach”). If a nanomaterial does not have a very
fast dissolution rate or a slower dissolution rate than its non-nano
counterpart, the black arrow down in Fig. 1 should be followed and
the nanospeciﬁc behaviour and effects should be further evaluated,
both for the kinetics and hazard (right side of the ﬁgure) and for the
exposure (on the left).
3.3. Exposure (phase I)
3.3.1. Exposure
The ﬁrst indication of exposure for workers and consumers is
based on a similar (qualitative) approach for identifying priorities
in exposure scenarios as described earlier in the NANoREG project
within work package 3 (NANoREG, 2015). In this report, exposure
scenarios of the highest potential occupational (and environ-
mental) exposure along the life cycle of currently marketed nano-
materials have been prioritised. The approach starts with the
identiﬁcation of the main applications inwhich the nanomaterial is
used. After this step, a life cycle for the nanomaterial and each of its
main applications is mapped, followed by the identiﬁcation of
identiﬁed uses (IU)2 and exposure scenarios (ES)3 for each life cycle
stage of each application (NANoREG, 2015).
3.3.2. Occupational exposure
In order to get a more speciﬁc understanding of the occupa-
tional exposure, the information gathered on identiﬁed uses (IU) is
coupled to Contributing Exposure Scenarios (CES) for each life cycle
stage of each application. CES are a set of speciﬁc conditions that are
corresponding to one worker’s or consumer’s activity. CES can be
directly linked to Process and Operational Conditions (PROCs) for
occupational exposure, for which ranking values have been deter-
mined within ECETOC Targeted Risk Assessment (TRA) (ECETOC,2 REACH deﬁnition of Identiﬁed Use (IU): a use of a substance on its own or in a
mixture, that is intended by an actor in the supply chain, including his own use, or a
use that is made known to him in writing by an immediate downstream user.
3 Exposure Scenarios (ES) should address the manufacture and identiﬁed uses.
According to REACH Annex I, registrants who are required to carry out a Chemical
Safety Assessment (CSA) with exposure assessment have to address all stages of the
life cycle of the substance including those resulting from the manufacture and
identiﬁed uses if they happen in the EU (e.g. the use of substances in articles).2012). The ranking of the PROCs within ECETOC TRA is mainly
based on dustiness, energy in the process, enclosure level of the
process, concentration in the preparation, duration of the activity,
ventilation and the use of personal protection (ECETOC, 2012;
Technical report 114). A ﬁrst ranking of the occupational exposure
can be obtained by combining the ranking values of the PROCs with
the estimated production volume of the nanomaterial of the
application (see Fig. 1 and Table 2). Also the most important
route(s) of exposure are important for further determination of the
strategy in the next phase of the approach.
3.3.3. Consumer exposure
For consumer exposure, no ranking of the exposure scenarios
was performed earlier in the NANoREG project (NANoREG, 2015),
because of the absence of information on the main determinant of
consumer exposure (the transfer factor4). However, when the main
applications are known inwhich the nanomaterial is used, themost
important exposure aspects for phase I of the proposed approach
can be selected based on information from NANoREG (2015), RIVM
(2015) and Wijnhoven et al. (2009). For consumer exposure, the
ﬁrst ranking is based on the production volume of the nanomaterial
in the application in combination with the way the nanomaterial is
incorporated in the consumer product (ﬁxed within a matrix or
freely available) (see Table 3). Products containing freely available
nanoparticles suspended in liquids or airborne aerosols (e.g. spray
applications) are expected to cause a higher consumer exposure
than products inwhich the nanomaterials are ﬁxed or incorporated
into a solid matrix (e.g. a bicycle frame). However, it is not always
clear if and how the nanoparticles are ﬁxed in the matrix of the
product and if they will stay ﬁxed or migrate, evaporate, wash out,
wear off, etc. during the use of the product. In addition, the most
important route(s) of exposure are important for further determi-
nation of the strategy in the next phase of the approach.
3.4. Kinetic and hazard aspects (phase I)
3.4.1. Rigid biopersistent HARN
One of the established mechanisms of toxicity of nanomaterials
is the potential of rigid and biopersistent high aspect ratio (ﬁbre-
like) nanomaterial (HARN) to cause “frustrated phagocytosis” by
macrophages after inhalation. This may lead to mesothelioma, a
speciﬁc form of cancer also known from exposure to asbestos
(Donaldson et al., 2010). Information needed for determining
whether a nanomaterial is a potential “rigid biopersistent HARN”,
includes the aspect ratio, rigidity as well as the biopersistence of
the nanomaterial under investigation. Rigid biopersistent HARN
materials with a length (L) of 5 mm, a diameter (D) of < 3 mmand a
L/D ratio of > 3, should either be substituted by an alternative4 Transfer factor is the fraction (0e1) of the substance transferred from the
product to the air, mouth or skin and represents a realistic worst-case dose avail-
able for exposure.
Table 3
Ranking of the consumer exposure potential in phase I based on production volume
and way of incorporation in the exposure matrix (free/ﬁxed) of the most important
consumer exposure scenarios within the life cycle of each application of the
nanomaterial.
Fixed in matrix/free Production volume
high medium low
free high high high
ﬁxed in matrix medium low low
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of health effect. This would mean avoiding most elements in phase
II and III of our approach and instead target information gathering
on the potential to cause mesothelioma (follow red arrow to the
box “Information gathering for targeted risk assessment”).3.4.2. Reactivity acellular
One of the most important hypotheses of nanospeciﬁc toxicity is
the increased surface reactivity of nanomaterials due to their
relatively large surface-to-volume ratio and sometimes also surface
modiﬁcation. Due to the relatively large surface-to-volume ratio
and speciﬁc functionalisation of nanomaterials, the reactivity of
nanomaterials can be enhanced compared to non-nanomaterials.
This reactivity may trigger the generation of reactive oxygen spe-
cies (ROS), leading to oxidative stress and subsequent inﬂammation
in biological tissues.
For metal and metal oxide nanoparticles, the surface reactivity
can for example be predicted using the conduction band energy
levels in combination with the solubility (Zhang et al., 2013). Based
on this publication, metal and metal oxide particles can be ranked
for their potential to cause oxidative stress in vitro as well as acute
inﬂammation after inhalation in vivo. For other nanomaterials and
other exposure routes, a ﬁrst indication on the reactivity of nano-
materials can be obtained by using acellular assays, for example by
measuring ROS (reactive oxygen species) formation or FRAS (Ferric
Reducing Ability of Serum) (Arts et al., 2015; Hsieh et al., 2013; Nel
et al., 2014). It should be noted that these assays only provide a ﬁrst
indication of the oxidative properties, since the local environment,
i.e. cell culture media in vitro or body ﬂuids in vivo, can inﬂuence
the reactivity of the nanomaterials in various ways, for example by
containing antioxidants or by altering the nanoparticles surface due
to biomolecule corona formation (Riebeling et al., 2016). The results
in the band gap analysis or acellular reactivity assays are used to
deﬁne further hazard ranking or subgroups (see Table 4). In addi-
tion, the results can give direction to further investigation of the
reactivity in cellular environments in phase II.Table 4
Further hazard ranking in phase I based on classiﬁcation and reactivity.
Reactivity Classiﬁcation
high medium low
high high high medium
low high medium low3.4.3. Hazard classiﬁcation of non- or similar NM
Another important indication on the toxicodynamics of a
nanomaterial can be obtained by looking at the hazard classiﬁca-
tion of the chemical components of the nanomaterial (the non-
nanomaterial) or a similar nanomaterial. It can be expected that
nanomaterials made of chemical components that are classiﬁed to
be for example genotoxic or sensitising will also have genotoxic
and/or sensitising properties. Although there may be differences
with respect to the critical dose levels and target organs, the pos-
sibilities to use read-across and grouping for these speciﬁc end-
points based on the hazard classiﬁcation of the non-nanomaterial
or similar nanomaterials might be considered (follow the arrow in
Fig. 1 towards the box “Read-across?”).
Guidance on categorisation and read-across for chemicals has
recently been published by ECHA and OECD (ECHA, 2013; OECD,
2014a,b; ECHA, 2016). The use of read-across and groupingprimarily based on the hazard classiﬁcation of non-nanomaterials
or similar nanomaterials is probably only feasible and regulatory
acceptable if this would lead to a classiﬁcation of the nanomaterial
into the highest category which requires risk reducing measure-
ments that would prevent or minimise human exposure in all life
cycle stages of the nanomaterial. If the chemical components of the
nanomaterial (the non-nanomaterial) or a similar nanomaterial are
not classiﬁed or if no (non-nano) counterpart can be identiﬁed, this
does not mean that the nanomaterials will not cause these speciﬁc
health effects. Further evaluation of the other elements related to
the kinetics, toxicity and exposure in phase II is then recommended
by following the orange arrow down in Fig. 1.3.5. Output phase I: prioritisation and ranking
Based on the information on size, shape and dissolution rate in
water obtained in the ﬁrst boxes of phase I, a ﬁrst ‘red’, ‘green’ or
‘orange’ ﬂag can be assigned to a nanomaterial as follows:
a) materials that have the highest potential to be hazardous
(ﬂagged red),
b) materials for which the classical (non-nanomaterial) risk
assessment approach can be performed (ﬂagged green) and
c) materials that need further evaluation (ﬂagged orange).
Within the orange group further ranking for prioritisation can
be obtained by combining further exposure and hazard ranking to
indicate a high, medium or low potential to cause harmful effects
within the life cycle of each application of the nanomaterial. The
kinetic behaviour is not explicitly included in this further ranking,
but is already implicitly taken into account by only including
nanomaterials that do not have a fast dissolution in water in the
orange group.
Further exposure ranking for occupational exposure is based on
the production volume of the nano-enabled application and the
PROCs of the exposure scenarios within the life cycle of each
application of the nanomaterial. Further exposure ranking for
consumer exposure is based on the production volume of the nano-
enabled application and the incorporation of the nanomaterial into
the matrix within the life cycle of each application of the nano-
material.
Further hazard ranking is based on classiﬁcation and reactivity:
 If one of the chemical components of a nanomaterial or a similar
nanoform is classiﬁed as carcinogenic, mutagenic or reprotoxic
(CMR, all categories), this nanomaterial is ranked ‘high’ with
respect to its hazard. The medium classiﬁcation category de-
scribes nanomaterials that are not classiﬁed as CMR but as
(respiratory) sensitisers or irritating substances, whereas a
material with only acute toxicity or no classiﬁcation for toxicity
is ranked low.
 If a nanomaterial has a high reactivity as predicted by the band
gap analysis for metal andmetal oxide nanoparticles or acellular
ROS or FRAS assays for non-metal nanomaterials, it is also
ranked ‘high’ with respect to its hazard. At the moment, the
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the assays.
 If the chemical components or similar nanoforms are not clas-
siﬁed and the nanomaterial does not have a high reactivity, the
nanomaterial is ranked ‘low’ with respect to its hazard. The total
hazard ranking results in the medium category when the clas-
siﬁcation is medium with a low reactivity, or when the classi-
ﬁcation is low with a high reactivity (Table 4). If no information
on the hazard classiﬁcation or reactivity is available, the mate-
rial will be ranked ‘high’ with respect to its hazard.
Combining the exposure ranking with the hazard ranking of the
most important occupational and consumer exposure scenarios
within the life cycle of each application of the nanomaterial gives a
further ranking in three subgroups to indicate a high, medium or
low potential to cause harmful effects.
Please note that ‘low’ in Table 5 does not mean that further
action for risk assessment is not needed. Information in line with
regulatory requirements needs to be complete. However, this
grouping (high, medium, low) can be used for prioritisation as
indicated in the introduction.Table 5
Combined ranking of potential exposure and hazard in phase I of themost important
occupational and consumer exposure scenarios within the life cycle of each appli-
cation of the nanomaterial.
Exposure Hazard
high medium low
high high high medium
medium high medium medium
low medium low low3.6. Output phase I: information used in phase II
The materials that are ﬂagged ‘green’ or ‘red’ will not enter
phase II of this ﬂow chart. The materials that are ﬂagged ‘green’will
need to be evaluated according to the classical non-nanomaterial
risk assessment approach. The materials that are ﬂagged ‘red’ will
skip most elements in phase I, II and maybe also III, to enable tar-
geted information gathering on the potential to cause
mesothelioma.
The group of materials that are ﬂagged ‘orange’ will enter phase
II. The rankings as described in the previous paragraphs are not
used in phase II as such. However, the information on which these
subgroups are based is used to give direction to those elements that
should be addressed in phase II by preference. The information
indicating which elements are most important is different for each
exposure situation and should be evaluated on a case-by-case basis.
Although it is not possible to describe this for each situation, an
attempt to a general description of which information of phase I
indicates which type of information is most relevant to obtain in
each of the boxes in phase II is given in the paragraphs underneath.
In addition, a few speciﬁc examples are described to give some
more insight into this process.
4. Description phase II
As depicted with the blue circles in Fig. 1, the most important
route(s) of exposure is (are) key in determining which type of in-
formation is relevant to obtain in each of the boxes in phase II. The
route of exposure also indicates the relevant media for testing the
dissolution rate and also the speciﬁc in vitromodels (cell types and
endpoints) to be investigated. In addition, information on thehazard classiﬁcation of the chemical components of the nano-
materials may also point towards relevant cell types and endpoints
to be investigated.
Relevant cell types for in vitro assays on the cytotoxicity,
immunotoxicity and genotoxicity can be selected based on the in-
formation on the dissolution rate in relevant media and in vitro
absorption together with the limited amount of knowledge avail-
able on the absorption, distribution and translocation of nano-
materials (in general).
Below a more detailed description of the type of information
and possible methods to generate this information is given for each
of the boxes in Fig. 1. Most information needed in the second phase
can be obtained through analytical and in vitro assays. An overview
of the relevant information for going through the entire ﬂow chart
is given in Table SI-1 of the Supplementary information.
4.1. Exposure (phase II)
4.1.1. Occupational exposure
In the second phase, it is proposed to extend the information
obtained on the occupational exposure in the ﬁrst phase with in-
formation on the exposure pattern (frequency and duration),
physical form and concentration (in air) or amount (deposited on
skin). These determinants were selected because they have the
largest inﬂuence on the ﬁnal ranking score in the NANoREG report
(NANoREG, 2015) and information on these determinants is
generally available for most exposure scenarios.
Using the additional information further ranking of the most
important occupational exposure scenarios is possible.
4.1.2. Consumer exposure
For consumer exposure, it is proposed to obtain additional in-
formation on the exposure pattern (including direct or indirect
exposure, frequency and duration), physical form, amount used
and/or amount available for exposure in the second phase. This
selection was based on ECETOC TRA (ECETOC, 2012), ConsExpo
Nano (RIVM, 2015) and Wijnhoven et al. (2009). The amount
available for exposure is based on the release out of the matrix of a
product, which is often very difﬁcult to measure. However, based
on the product description, an indication of the potential release of
the nanomaterial out of the matrix of the product can be obtained.
In general, the potential release from solid consumer products is
expected to be less than the release from liquid or powdered
products. In addition, incorporation of the nanomaterial into the
solid matrix of the consumer product itself (e.g. incorporation of
silver nanomaterials into textile ﬁbres) will probably lead to less
release of the nanomaterial than applying a coating to the surface of
a solid consumer product (e.g. spraying a coating containing silver
nanoparticles onto the textile product). If no information is avail-
able, the assumption that all material is releasedmay be considered
as worst-case assumption.
Using the additional information, further ranking of the most
important consumer exposure scenarios is possible.
4.2. Kinetic and hazard aspects (phase II)
4.2.1. Dissolution rate (relevant media)
Recently the different analytical methods available to measure
solubility of nanomaterials have been described (Tantra et al.,
2015). Although a wide variety of techniques are available with
the capability to measure total dissolved species or free ions, but
not both, only a limited number of them is suitable for measure-
ment in biological media. Electrochemical and colorimetric based
detection schemes are able to measure the latter, whilst atomic
spectrometry based techniques are able to measure the former if
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ultracentrifugation.
In general, the exposure route is determining what a relevant
medium is. For the inhalation route of exposure, dissolution in lung
airway epithelial lining ﬂuid and (macrophage) phagolysosomal
simulant ﬂuid is relevant. The oral route can be covered by
measuring dissolution of nanomaterials in food matrices, gastro-
intestinal tract simulation ﬂuid and macrophage phagolysosomal
ﬂuid. For dermal conditions, the dissolution rate in artiﬁcial sweat
could be used.
In general, the dissolution rate in relevant media can provide
information on the forms or speciation (coated or uncoated nano-
particle, agglomerate, aggregate, ionic and molecular form) of the
nanomaterial when it comes into contact with the relevant areas in
the human body, when it is absorbed andwhen it is distributed and
translocated into speciﬁc organs and/or cellular compartments.
This information is very important, because the extent and rate in
which the nanomaterial transforms into these different forms of
the material (including the extent to which it is dissolved) greatly
inﬂuences its kinetic behaviour and toxicity. For some nano-
materials, the toxicity is mainly determined by the extent and rate
in which it releases ions, while the toxicity of other nanomaterials
is mainly determined by the particulate properties that induce an
inﬂammatory response (Cho et al., 2012). It should be noted that
more complex nanomaterials cannot be seen as a homogeneous
objects when evaluating the solubility rate.
4.2.2. Absorption (barriers)
In vitro test methods simulating pulmonary (MucilAir™) or
gastrointestinal barriers (Caco2) have been developed within the
NANoREG project based on existing protocols (ECVAM, 2013), but
these still need to be validated. Other physiological barrier models
based on cell cultures and ex vivo tissues have also been used
within the NANoREG project to simulate the blood brain barrier
(Domínguez et al., 2014) and the oral mucosa barrier. To investigate
uptake through the skin, an accepted in vitro test method is avail-
able (i.e. the in vitro skin absorption method in accordance to OECD
TG 428) but it still needs to be validated for nanomaterials.
For the inhalation route, generally only a very small percentage
of insoluble nanomaterials is translocated or accumulated in
extra-pulmonary organs. Studies with partially soluble nano-
materials typically show a larger percentage of particle trans-
location to extra-pulmonary organs as compared to the insoluble
particles. However, it should be noted that with the current
analytical tools it is difﬁcult to determine whether either the
particles themselves or another form of the material (e.g. molec-
ular or ionic) are translocated.
For the oral route, it is known that the vast majority of ingested
nanomaterials are rapidly passing through the gastrointestinal tract
(GT) and are excreted via faeces. Nanomaterial absorption in the GT
decreases with increasing material size (Schleh et al., 2012; Powell
et al., 2010). Therefore, aggregation and agglomeration state of the
nanomaterial inﬂuences its bioavailability. The rate of nanomaterial
agglomeration in different vehicles is affected by the pH level. The
different pH conditions in the GT and the presence of digestion
enzymes might inﬂuence the behaviour (i.e. ion release, dissolu-
tion) of some nanomaterials. It has been suggested that positively
charged materials exhibit poor bioavailability due to electrostatic
repulsion and mucus entrapment (Hoet et al., 2004; Kermanizadeh
et al., 2015). For nanomaterials dissolution rates in physiologically
relevant media like gastrointestinal simulated ﬂuid has been sug-
gested to be the decisive factor determining oral uptake.
Nanomaterial size appears to be highly signiﬁcant for dermal
penetration. Materials larger than 100 nm in one or more di-
mensions do not seem to penetrate through the stratum corneum.Aggregation and agglomeration state is crucial in the degree of
penetration and potential translocation (Kermanizadeh et al.,
2015).
Information on absorption into the body provides information
on the need to consider only local or also systemic effects. How-
ever, it is often difﬁcult to distinguish between complete absence
and little transport in in vitro barrier systems. For nanomaterials
even very little uptake may result in relevant internal levels due to
low elimination and accumulation in time. This should be
considered when data from in vitro barrier models is used.
Currently, the scientiﬁc knowledge on the behaviour of nano-
materials within the human body is not sufﬁciently developed to
predict the distribution and translocation of nanomaterials
throughout the human body after inhalation, dermal or oral
exposure. Without speciﬁc modiﬁcations, most poorly soluble
nanomaterials that reach the systemic circulation are mainly
distributed to tissues that are rich in reticuloendothelial cells,
such as liver and spleen. However, the nanospeciﬁc physiologi-
cally based pharmacokinetic (PBPK) models developed to date
mostly concern PBPK models in rats and mice for a speciﬁc type of
nanomaterial (Bachler et al., 2013; Lin et al., 2015, 2016). Devel-
opment of more general PBPK models and extrapolation of these
models to humans should, in the near future, make it possible to
predict the distribution and translocation of several types of
nanomaterials in the human body. In the meantime, one may use
absorption rates in combination with intravenous kinetic models
developed for speciﬁc nanomaterials to estimate internal dose
levels, taking into account the physicochemical properties of the
nanomaterial and the nanomaterial on which the kinetic model is
based (e.g. Van Kesteren et al., 2015). Based on these estimated
internal dose levels relevant internal barrier models and relevant
cell types for in vitro assays can be selected. When, for example, a
nanomaterial is likely to reach the systemic circulation, in vitro
blood-brain or placental barrier models might be relevant, though
it should be noticed that such in vitro models cannot distinguish
between low and no translocation. For nanomaterials that are
likely to be distributed to the liver, hepatic cell lines should be
considered for in vitro genotoxicity testing.
4.2.3. Aggregation and agglomeration
Some of the analytical methods used to determine if a material
meets the criteria of the EC recommendation (JRC, 2012; 2014a; b;
2015; De Temmerman et al, 2014) can also be used to determine the
aggregation and agglomeration. The most suitable methods should
be selected taking the environment or matrix surrounding the
nanomaterial into account. If inhalation is one of the most impor-
tant routes of exposure, information on the aggregation and
agglomeration as estimated by the size distribution of the aero-
dynamic diameter of the aerosol is very important to determine the
deposition in the respiratory tract and subsequent translocation
from the lungs to the blood stream, which are largely dependent on
the diameter of the aggregated or agglomerated nanomaterials.
The largest level of deposition is at the smaller sub-micron size
range (<0.1 mm), with particles able to penetrate the trachea-
bronchial and alveolar regions. Deposition of particles in the
range >0.5 mm is related to their aerodynamic diameter whilst for
particles <0.5 mm deposition is related to their diffusion equivalent
diameter (Schulz et al., 2000).
The average agglomeration number (AAN) has been proposed to
assess the dispersibility of nanomaterials (Arts et al., 2015, 2016).
Nanomaterials that remain dispersed as constituent particles (with
AAN <3) are deﬁned as ‘mobile’, since they may potentially move
between body compartments.
Information on the aggregation and agglomeration of a nano-
material can be used to predict the ability of absorption,
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selection of relevant internal barrier models and relevant cell types
for in vitro assays.
4.2.4. Cellular uptake, attachment and interaction
Information on the cellular uptake, attachment and interaction
of nanomaterials can be studied using ﬂow-cytometry, microscopy
and inductively coupled plasmamass spectrometry (ICP-MS). Flow-
cytometry and ICP-MS can measure quantitatively, but cannot
distinguish between externally attached and fully internalised
nanomaterials. Furthermore, ICP-MS cannot distinguish between
dissolved ions and nanoparticles and can only be used for electron-
dense material and not for detecting liposomes, polymers, or
dendrimers. Confocal microscopy gives qualitative insight into the
subcellular localisation and three-dimensional structure of parti-
cles. Transmission electron microscopy (TEM) can be used to
conﬁrm subcellular particle localisation and three-dimensional
structure with high resolution. This method allows semi-
quantitative assessments, but the procedure is time-consuming.
Combining TEM with energy-dispersive X-ray spectroscopy (EDX)
makes it possible to conﬁrm the elemental composition of the
nanoparticles (Kettiger et al., 2013).
Several in vitro assays have been tested and further developed
within the NanoREG project based on standard toxicity protocols
developed for pharmaceutical products, but these still need to be
validated for nanomaterials. One may also consider studying the
cellular uptake, attachment and interaction in the same in vitro
assay(s) used to investigate the cytotoxicity and cytokine induction.
Information on cellular uptake, attachment and interaction
gives a ﬁrst indication on the possible mechanisms of toxicity, such
as damaging different cellular targets through the release of ions,
the generation of ROS or the binding and interaction with intra-
cellular proteins (Fr€ohlich, 2013; Nel et al., 2009). For example,
direct interaction of a nanomaterial with DNA can only occur if the
nanomaterial is taken up by the cell and is able to reach the DNA
within the nucleus.
4.2.5. In vitro cytotoxicity, ROS and cytokines
There are many in vitro assays based on a range of cell types and
endpoints to investigate cytotoxicity, ROS generation and cytokine
induction. Several in vitro assays have been tested and further
developed within the NANoREG project. These include standard
protocols for MTS assay, the neutral red assay (adapted from OECD
432), micronucleus assay (OECD 487), mammalian gene mutation
test (OECD490), colony forming efﬁcacy (OECD 476), the comet
assay (Collins, 2004), ROS detection by dichloroﬂuorescin diacetate
(DCFDA) and interleukin expression upon exposure of NM to cells,
but these still need to be validated for nanomaterials since in
several cases the nature of the nanomaterials may interfere with
detection methodologies (OECD, 2013).
Some of these assays allow studying the cellular uptake,
attachment, interaction, cytotoxicity, ROS generation and/or cyto-
kine induction in the same in vitro system. The appropriate assay
should be selected taking into account that nanomaterials often
showmajor interference with the in vitro assay or read-out system.
Furthermore, it is essential to test for endotoxin contamination
before studying the immunotoxicity of nanomaterials in vitro
(Dobrovolskaia et al., 2009, 2016).
As for non-nanomaterials, the results of these in vitro assays
cannot be used to predict Human Limit Values. However, they will
give insight in the potential mechanisms of toxicity. Measuring the
levels of pro-inﬂammatory cytokines and other inﬂammatory me-
diators may give insight into the mechanisms of the immunomo-
dulating effects of a nanomaterial in vitro, such as inﬂammasome
activation or dendritic cell maturation (Elsabahy and Wooley,2013). In addition, they may give a ﬁrst indication on the ability
of the nanomaterials to cause immunotoxic effects in vivo. Cellular
ROS assays provide information on the ability of nanomaterials to
generate ROS within a cellular environment. Measuring the cyto-
toxicity is important for a good interpretation of the results of the
in vitro cytokine and genotoxicity assays. In addition, in vitro cyto-
toxicity assays may give insight into the mechanisms of cytotox-
icity, including damaging the plasma membrane, mitochondria,
lysosomes or DNA through the release of ions, the generation of
ROS or the binding and interaction with intracellular proteins
(Fr€ohlich, 2013; Nel et al., 2009).
4.2.6. In vitro skin and eye irritation tests
Several in vitro skin and eye irritation tests are available,
including the rat skin transcutaneous electrical resistance (TER) test
(OECD TG 431), the reconstructed human epidermis (RHE) skin
irritation test (OECD TG 439), the Bovine Cornea Opacity Perme-
ability (BCOP) test (OECD TG 437), the isolated chicken eye (ICE)
test (OECD TG 438), and an in vitro cell assay (OECD TG 460). These
assays were developed for the evaluation of skin and eye irritation
of chemical substances, but not all of them have been validated for
chemical substances yet and none of them have been validated for
nanomaterials (SCENIHR, 2015).
Information on in vitro skin and eye irritation gives an indication
on the ability of the nanomaterials to cause these effects in vivo.
4.2.7. Cell transformation assay
Several in vitro cell transformation assays (CTAs) are available to
assess initiation and tumour promotion potentials, but none of
them have been validated for chemical substances or nano-
materials. CTAs measure induction of phenotypic alterations char-
acteristic of tumourigenic cells. CTAs mimic some key stages of
in vivo multistep carcinogenesis and have been shown to have a
good concordance with rodent bioassay results, detecting both
genotoxic and non-genotoxic carcinogens (Creton et al., 2012).
Information on in vitro cell transformation ability gives an
indication on the possible mechanisms of carcinogenicity and an
indication on the ability of the nanomaterials to cause these types
of effects in vivo.
4.2.8. In vitro genotoxicity
The strategy for in vitro genotoxicity testing of nanomaterials
needs to include the detection of the most relevant events for the
multistep process of malignancy (gene mutations, clastogenicity
and aneugenicity). At each stage of the testing strategy, expert
judgment is necessary to decide on the relevance of a result
considering the existing weight of evidence.
Tests for genemutation inmammalian cells can be used, e.g., the
mouse lymphoma TK gene mutation assay (MLA) OECD TG 476
which uses the autosomal thymidine kinase (Tk) gene as a reporter
of mutations in the L5178Y/Tk ± mouse lymphoma cell line or the
hypoxanthine guanine phosphoribosyltransferase (Hprt) gene for-
ward mutation assay in Chinese hamster ovary (CHO) cells (Silva
et al., 2005). In addition, the chromosomal aberration and the
cytokinesis-blocked micronucleus (CBMN) tests are sensitive and
reliable assays for the analysis of chromosome damage in
mammalian cells. The former is used for detection of structural
chromosome aberrations, i.e., chromatid- and chromosome-type
breaks and rearrangements in cultured mammalian cells (OECD,
1997). The CBMN test allows the detection of micronuclei in the
cytoplasm of interphase cells (Fenech, 2000) containing whole
chromosomes (aneugenic events) or chromosome fragments
(clastogenic events) during cell division (OECD, 2010). On the other
hand, a genotoxicity assay that has been strongly recommended for
regulatory purposes is the alkaline single cell electrophoresis, or
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sensitive and cost-effective method for the identiﬁcation of DNA
strand breaks and oxidative DNA lesions (formamido-pyrimidine-
DNA-glycosylase modiﬁed comet assay) having the added advan-
tage of requiring a very low quantity of substance or material for
analysis compared to other in vitro genotoxicity assays. Several
in vitro genotoxicity assays have been tested and further developed
within the NANoREG project (adapted from OECD 487, OECD 476
and OECD 490), but these still need to be validated for
nanomaterials.
Information on in vitro genotoxic mechanisms gives an indica-
tion on the possible genotoxicity and the ability of the nano-
materials to cause cancer. Positive results indicate that these
genotoxic endpoints might need to be investigated in vivo (or read-
across to in vivo studies with similar materials should be consid-
ered). Before performing in vivo tests kinetic information is needed
to assess which target tissues might be reached (including germ
cells for potential reproductive effects). Negative results might in
the future be sufﬁcient to rule out these genotoxic effects, provided
the most relevant test methods, cell types, and dose levels have
been tested according to high quality standards to gather enough
weight of evidence. In the future, when more scientiﬁc knowledge
becomes available, it might also be possible to use in silicomethods
to build stronger predictions (e.g. on validated nano-QSARs) and
support the weight of evidence.
4.3. Output phase II
In contrast to the output of phase I, the information obtained in
phase II does not lead to a ranking of nanomaterial applications.
However, the output gives direction to the information that needs
to be obtained in phase III.
5. Description phase III and further
In phase III, additional information on other determinants or
exposure measurements may be obtained to give further insight
into the risks associated to critical exposure scenarios. Guided by
information obtained on the kinetics and hazard in phase II, in vivo
studies to conﬁrm the potential absorption, irritation, immuno-
toxicity and genotoxicity indicated by the in vitro studies might be
needed. Which information from phase II may trigger the type of
information to be gathered in phase III (and further) is different for
each nanomaterial application and exposure situation. Although it
is not possible to describe this for each situation, a general
description of which information of phase II may trigger the need to
generate which type of information in phase III is given in the
paragraphs underneath. An overview of the relevant information
for going through the entire ﬂow chart is given in Table SI-1 of the
Supplementary Information.
Positive results of in vitro absorption assays may trigger further
investigation of the ability of a nanomaterial to become systemi-
cally available (and possibly cause systemic effects) in an in vivo
repeated dose kinetic and toxicity test. Negative results of in vitro
absorption assays should be interpreted with care, because it is
often difﬁcult to distinguish between complete absence and little
transport in in vitro barrier systems. Therefore, negative results may
indicate the need for more information on the dissolution, trans-
formation and systemic toxicity of the nanomaterials under
investigation. Together with information on the size, aggregation,
agglomeration as well as information on the lack of absorption,
systemic distribution and toxicity of similar nanomaterials or non-
nanomaterials, the possibility of read-across might be considered.
The results of in vitro assays investigating cellular uptake,
attachment, interaction, cytotoxicity, ROS generation and/orcytokine induction will give insight in the possible mechanisms of
toxicity, whichmay trigger themeasurement of speciﬁc parameters
(cytokines, oxidative stress markers) in in vivo studies. Eventually
this may also highlight the relevance of speciﬁc endpoints to be
considered.
Positive results of in vitro genotoxic assays may trigger further
investigation of genotoxicity by in vivo genotoxicity testing (or
read-across to in vivo studies with similar materials should be
considered). Before in vivo genotoxicity tests are performed, infor-
mation on the kinetics of the nanomaterial is needed, to enable the
selection of the relevant tissues.
Positive results of in vitro cell transformation and in vivo geno-
toxicity studies together with observed systemic availability, ex-
pected accumulation and toxicity (e.g. inﬂammatory effects) from
in vivo repeated dose toxicity tests may trigger long-term repeated
dose kinetic and toxicity testing to rule out accumulation and long
term effects, including carcinogenic, cardiovascular and adverse
reproductive effects.
6. Discussion and conclusions
Performing risk assessment for each individual nanoform on a
case-by-case basis would require a lot of experimental animals as
well as time, effort, and money. The proposed approach, based on
six elements, provides alternative ways to address the risk assess-
ment of nanomaterials, by prioritising those applications with the
highest potential health risks, identifying the most important in-
formation to address the nanospeciﬁc issues or perform risk
assessment across different nanoforms (e.g. using (Q)SARs,
grouping or read-across).
The prioritisation is just a ﬁrst indication on the potential health
risk of a nano-enabled application. Because it should only be used
for prioritisation, applications within the ‘low’ risk category should
not be disregarded for further evaluation. Potential health risks of
all categories (‘low’, ‘medium’ and ‘high’) still need to be veriﬁed
and reﬁned. Possibly, in the ﬁrst phase of the approach, not all
exposure situations have been identiﬁed or unexpected tox-
icokinetic or toxicodynamic effects have not been identiﬁed.
The proposal suggests speciﬁc steps to gather certain pieces of
key information. It should be noted that these selected pieces of
information might not always be easy to obtain or generate. Within
REACH, industry is responsible to provide sufﬁcient information to
ensure safe use of the application of the nanomaterial. These in-
formation requirements can be met in different ways, including the
use of read-across and grouping. The methods proposed to obtain
the selected pieces of information should be seen as suggestions. In
case similar information can be obtained with other methods or
tests, whichmight for example appear (scientiﬁcally) more suitable
for speciﬁc cases, these can also be used. Clearly, the completeness,
quality and uncertainty of the information are of utmost impor-
tance, but this is not always possible to verify. Without good quality
data, and the ability to assess the quality of the data, the informa-
tion obtained or generated might be inadequate for risk
assessment.
It is also widely accepted that the scientiﬁc knowledge on
nanomaterials is not yet sufﬁcient for deﬁning all benchmarks or
cut-off values needed within this approach or for broad application
of nanospeciﬁc (Q)SARs, grouping and read-across tools. With the
current approach it is possible to identify those situations where
deﬁning such benchmarks or cut-off values is likely to become
feasible in the near future, and which type of data needs to be
generated for scientiﬁc justiﬁcation. Some of the benchmarks and
cut-off values are rather general and applicable to many different
situations, while others are more speciﬁc for the nanomaterial
application and exposure situation. To give an indication of the type
S. Dekkers et al. / Regulatory Toxicology and Pharmacology 80 (2016) 46e59 57of data that is needed for the scientiﬁc justiﬁcation of these cut-off
values, a more general and a more speciﬁc example of a cut-off
value are described. Furthermore, an outlook on the feasibility to
obtain this type of data in the near future is given. Only the type of
data, not the amount and level of conﬁdence needed for regulatory
acceptability is described.
Within the ﬁrst phase of the approach, a cut-off value on
dissolution rate in water is needed to distinguish those materials
that fall apart into their molecular or ionic form before they reach
the human body from those materials that have a slower dissolu-
tion rate enabling at least some of the material to reach the human
body as a nanomaterial. Although no exact cut-off value has been
proposed, the dissolution rate needs to be very fast (i.e. close to
instantly dissolved) to justify the use of the “classical (non-nano-
material) approach”. The type of data needed to deﬁne this cut-off
value is data on the dissolution rate of a large systematic set of
different types and variations of nanomaterials in water together
with information on the forms or speciation (coated or uncoated
nanoparticle, agglomerate, aggregate, ionic and molecular form) of
these nanomaterials when they come into contact with the human
body. The latter is difﬁcult to obtain, as it requires a lot of knowl-
edge on the behaviour of different types of nanomaterials in
different types of environments, including air, water and different
product matrices. However, it might be possible to deﬁne a con-
servative cut-off value for dissolution rate in water based on worst
case assumptions in the near future, taking relevant time-frames
for hazard assessment into account.
A more speciﬁc example are the cut-off values to predict the
acute inﬂammatory effects of metals and metal oxides nano-
particles after inhalation as proposed by Zhang et al. (2013). These
cut-off values are based on analytical data (on conductivity band
gap and dissolution in bronchial epithelial growth medium),
in vitro data (on the potential to cause oxidative stress) and in vivo
data (on the acute inﬂammation after inhalation) of a limited set
of metal and metal oxide nanoparticles. The data needed for a
more thorough scientiﬁc justiﬁcation are similar data of a larger
systematic set of other (combinations of) metal and metal oxide
nanoparticles. It seems feasible to obtain this type of data in the
near future.
To make the proposed approach work, multiple benchmark and
cut-off values need to be deﬁned for basically each of the aspects
described throughout all three phases. Therefore, the approach still
needs to be further developed and tested by guiding several case
studies through the different phases. These case studies will also
make it possible to obtain a more complete overview of those sit-
uations where deﬁning benchmarks and cut-off values is likely to
become feasible in the near future. In general, systematic sets of
high quality data are needed to identify, verify and validate which
nanomaterial characteristics inﬂuence which aspect of the expo-
sure, kinetics or toxicity.
The proposed approach, including the type of information
linked to the various elements and endpoints, is based on the
current state of knowledge and is ﬂexible enough to accommodate
future insights and knowledge of nanomaterials. Further elabora-
tion and reﬁnement of especially phase III (and further) is needed
based on experience with case studies. Although the current
approach focusses only on the human risk assessment of nano-
materials, the approach can be expanded to environmental risk
assessment in the future.
To conclude, the proposed risk assessment strategy, which is
based on six elements, can be used to prioritise those nanomaterial
applications that may lead to high risks for human health. The
different phases of the ﬂow chart guide the user to the most
important information needed to address the nanospeciﬁc issues
within the risk assessment, depending on the speciﬁc nanomaterialapplication, life cycle stage and exposure situation. Furthermore,
the approach can also be used to identify those situations where
the use of nanospeciﬁc grouping, read-across and (Q)SAR tools is
likely to become feasible in the future, and to point towards the
generation of the type of data that is needed for scientiﬁc justiﬁ-
cation, which may lead to regulatory acceptance of nanospeciﬁc
applications of these tools.
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